Evidence map›Paper›PMID 35641921›Full record

ArticleBMC cancer2022

Timing of adjuvant chemotherapy initiation and mortality among colon cancer patients at a safety-net health system.

Yan Lu, Aaron W Gehr, Rachel J Meadows, Bassam Ghabach, Latha Neerukonda, Kalyani Narra, Rohit P Ojha

Abstract read
In one paragraph

Article in BMC cancer, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Yan LuCenter for Epidemiology & Healthcare Delivery Research, JPS Health Network, 1500 S. Main Street, Fort Worth, TX, 76104, USA.
Aaron W GehrCenter for Epidemiology & Healthcare Delivery Research, JPS Health Network, 1500 S. Main Street, Fort Worth, TX, 76104, USA.
Rachel J MeadowsCenter for Epidemiology & Healthcare Delivery Research, JPS Health Network, 1500 S. Main Street, Fort Worth, TX, 76104, USA.
Bassam GhabachOncology and Infusion Center, JPS Health Network, 1450 8th Ave, Fort Worth, TX, 76104, USA.
Latha NeerukondaOncology and Infusion Center, JPS Health Network, 1450 8th Ave, Fort Worth, TX, 76104, USA.
Kalyani NarraOncology and Infusion Center, JPS Health Network, 1450 8th Ave, Fort Worth, TX, 76104, USA.
Rohit P OjhaCenter for Epidemiology & Healthcare Delivery Research, JPS Health Network, 1500 S. Main Street, Fort Worth, TX, 76104, USA. rojha@jpshealth.org.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundPrior studies reported survival benefits from early initiation of adjuvant chemotherapy for stage III colon cancer, but this evidence was derived from studies that may be sensitive to time-related biases. Therefore, we aimed to estimate the effect of initiating adjuvant chemotherapy ≤8 or ≤ 12 weeks on overall and disease-free survival among stage III colon cancer patients using a study design that helps address time-related biases.

methodsWe used institutional registry data from JPS Oncology and Infusion Center, a Comprehensive Community Cancer Program. Eligible patients were adults aged < 80 years, diagnosed with first primary stage III colon cancer between 2011 and 2017, and received surgical resection with curative intent. We emulated a target trial with sequential eligibility. We subsequently pooled the trials and estimated risk ratios (RRs) along with 95% confidence limits (CL) for all-cause mortality and recurrence or death at 5-years between initiators and non-initiators of adjuvant chemotherapy ≤8 or ≤ 12 weeks using pseudo-observations and a marginal structural model with stabilized inverse probability of treatment weights.

resultsOur study population comprised 222 (for assessing initiation ≤8 weeks) and 310 (for assessing initiation ≤12 weeks) observations, of whom the majority were racial/ethnic minorities (64-65%), or uninsured with or without enrollment in our hospital-based medical assistance program (68-71%). Initiation of adjuvant chemotherapy ≤8 weeks of surgical resection did not improve overall survival (RR for all-cause mortality = 1.04, 95% CL: 0.57, 1.92) or disease-free survival (RR for recurrence or death = 1.07, 95% CL: 0.61, 1.88). The results were similar for initiation of adjuvant chemotherapy ≤12 weeks of surgical resection.

conclusionsOur results suggest that the overall and disease-free survival benefits of initiating adjuvant chemotherapy ≤8 or ≤ 12 weeks of surgical resection may be overestimated in prior studies, which may be attributable to time-related biases. Nevertheless, our estimates were imprecise and differences in population characteristics are an alternate explanation. Additional studies that address time-related biases are needed to clarify our findings.

Indexed as

Colonic NeoplasmsAdultChemotherapy, AdjuvantHumansMedical AssistanceNeoplasm StagingOdds RatioAdjuvant chemotherapycolon cancerDisease-free survivalMortalityPrognosisQuality of careTiming

Identifiers

PMID35641921
PMCPMC9158363

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.